Weight loss and wasting in patients infected with human immunodeficiency virus

Clinical Infectious Diseases

Volumn 36, Issue SUPPL. 2, 2003, Pages

  Grinspoon, Steven ^a   Mulligan, Kathleen ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANTIRETROVIRUS AGENT; APPETITE STIMULANT; CANNABIS; DRONABINOL; GROWTH HORMONE; KETOTIFEN; MEGESTROL ACETATE; MUSCLE PROTEIN; NANDROLONE; OMEGA 3 FATTY ACID; OXANDROLONE; OXYMETHOLONE; PENTOXIFYLLINE; SOMATOMEDIN C; TESTOSTERONE ENANTATE; THALIDOMIDE;

ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; CARPAL TUNNEL SYNDROME; CHILD GROWTH; CLINICAL TRIAL; CONFUSION; CYTOKINE PRODUCTION; DIARRHEA; DIETARY INTAKE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; EUPHORIA; GLUCOSE INTOLERANCE; GROWTH DISORDER; GROWTH RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPOGONADISM; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIVER DYSFUNCTION; LOW DRUG DOSE; MALABSORPTION; MEDICAL ASSESSMENT; MENTAL DISEASE; MENTAL INSTABILITY; METABOLIC DISORDER; MORTALITY; MUSCLE ATROPHY; MUSCLE EXERCISE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE TRAINING; MYALGIA; NEUTROPENIA; NUTRITIONAL SUPPORT; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; VERTIGO; WASTING SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; APPETITE REGULATION; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYTOKINES; EXERCISE; GROWTH HORMONE; HIV INFECTIONS; HUMANS; MUSCLE WEAKNESS; STEROIDS; WEIGHT LOSS;

EID: 0037384062     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367561     Document Type: Review

References (104)

1. Serwadda D, Mugerwa R, Sewankambo N. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 1985;2: 849-52.
2. Mhiri C, Belec L, DiCostanza B, Georges A, Gherardi R. The slim disease in African patients with AIDS. Trans R Soc Trop Med Hyg 1992; 86:303-6.
3. Centers for Disease Control. HIV/AIDS surveillance report. 1997; 9: 18.
4. Wanke C, Silva M, Knox T, Forrester J, Speigelman, Gorbach S. Weight loss and wasting remain common complications in individuals infected with HIV in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803-5.
5. Moore RD, Chaisson RE. Natural history of HW infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-42.
6. Kotler D, Tierney A, Wang J, Pierson R, Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989; 50:444-7.
7. Chlebowski R, Grosvenor M, Bernhard N, Morales L, Bulcavage L. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989; 84:1288-93.
8. Guenter P, Muurahainen N, Kosok A, Cohan GR, Rudenstein R, Turner J. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr 1993; 6:1130-8.
9. Palenicek J, Graham N, He Y, et al. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr 1995; 10: 366-73.
10. Semba R, Caiaffa W, Graham N, Cohn S, Vlahov D. Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis 1995; 171: 1196-202.
11. Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Muller M. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr 1995; 8:239-46.
12. Ott M, Fischer H, Polat H, et al. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1995; 9:20-5.
13. Wheeler D, Gibert C, Launer C, et al. Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr 1998; 18:80-5.
14. Schwenk A, Beisenherz A, Romer K, et al. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment. Am J Clin Nutr 2000; 72:495-501.
15. Thiebaut R, Malvy D, Marimoutou C, Davis F. Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997. Groupe d-Epidemiologie Clinique du Sida en Aquitaine (GECSA). Eur J Epidemiol 2000; 16:633-9.
16. Yarasheski K, Zachwieja J, Gischler J, et al. Increased plasma Gln and Leu R(a) and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol 1998; 275:E577-E83.
17. Grinspoon S, Corcoran C, Rosenthal D, et al. Quantitative assessment of cross-sectional muscle area, functional status and muscle strength in men with the AIDS wasting syndrome. J Clin Endocrinol Metab 1999; 84:201-6.
18. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36(Suppl):3S-14S.
19. Silva M, Skolnik P, Gorbach S, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998; 12:1645-51.
20. Kotler D, Wang J, Pierson R. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985; 42:1255-65.
21. Sharkey S, Sharkey K, Sutherland L, Church D. Nutritional status and food intake in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1992; 5:1091-8.
22. Suttmann U, Ockenga J, Hoogestraat L, et al. Resting energy expenditure and weight loss in human immunodeficiency virus-infected patients. Metabolism 1993; 42:1173-9.
23. Ott M, Lembcke B, Fischer H, et al. Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr 1993; 57:15-9.
24. Schwenk A, Burger B, Wessel D, et al. Clinical risk factors for malnutrition in HIV-1-infected patients. AIDS 1993; 7:1213-9.
25. Sharpstone D, Murray C, Ross H, et al. Energy balance in asymptomatic HIV infection. AIDS 1996; 10:1377-84.
26. Paton N, Macallan D, Jebb S, et al. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. J Acquir Immune Defic Syndr 1997; 14:119-27.
27. Mulligan K, Tai V, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr 1997; 15:43-8.
28. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 1997; 82:1332-7.
29. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr 1999; 20:228-37.
30. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56.
31. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-32.
32. Working Group on Antiretroviral Therapy. National Pediatric and Family HIV Resource Center. Antiretroviral therapy and medical management of pediatric HIV infection. Pediatrics 1998; 102(4 Suppl):999-1085.
33. Grunfeld C, Pang M, Shimizu L, et al. Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992; 55:455-60.
34. Macallan D, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995; 333:83-8.
35. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in HIV-infected men: relationship to body composition, gonadal function and protease-inhibitor use. J Clin Endocrinol Metab 2000; 85:35-41.
36. Berger B, Ollenschlager G, Schrappe M, Stute A, Fischer M, Wessel D, Schwenk A, Diehl V. Nutrition behavior of malnourished HIV-infected patients and intensified oral nutritional intervention. Nutrition 1993; 9:43-4.
37. Dowling S, Mulcahy F, Gibney M. Nutrition in the management of HIV antibody positive patients: a longitudinal study of dietetic outpatient advice. Eur J Clin Nutr 1990; 44:823-9.
38. Kotler D, Tierney A, Culpepper-Morgan J, Wang J, Pierson R Jr. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. Jpn J Parenter Enteral Nutr 1990; 14:454-8.
39. Kotler D, Tierney A, Ferraro R, et al. Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr 1991; 53:149-54.
40. Singer P, Rothkopf M, Kvetan V, Kirvela O, Gaare J, Askanazi J. Risks and benefits of home parenteral nutrition in the acquired immunodeficiency syndrome. J Parenter Enteral Nutr 1991; 15:75-9.
41. Singer P, Rubinstein A, Askanazi J, et al. Clinical and immunologic effects of lipid-based parenteral nutrition in AIDS. J Parenter Enteral Nutr 1992; 16:165-7.
42. Cappell M, Godil A. A multicenter case-controlled study of percutaneous endoscopic gastrostomy in HIV-seropositive patients. Am J Gastroenterol 1993; 88:2059-66.
43. Melchior J, Chastang C, Gelas P, et al. Efficacy of 2-month total parenteral nutrition in AIDS patients: a controlled randomized prospective trial. AIDS 1996; 10:379-84.
44. Shabert J, Winslow C, Lacey J, Wilmore D. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition 1999; 15:860-4.
45. Miller T, Awnetwant E, Evans S, Morris V, Vasquez I, McIntosh K. Gastrostomy tube supplementation for HIV-infected children. Pediatrics 1995; 4:696-702.
46. Henderson R, Saavedra J, Perman J, Hutton N, Livingston R, Yolken R. Effect of enteral tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J Pediatr Gastroenterol Nutr 1994; 18:429-34.
47. Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. J Parenter Enteral Nutr 2000; 24:133-9.
48. Mulligan K, Rajicic N, Sattler F, et al. Protein and energy supplementation in weight (wt)-stable HIV-infected subjects with prior wt loss: randomized, double-blind study [abstract]. In: Program and abstracts of the 4th International Conference on Nutrition and HIV Infection, 2nd European Workshop on Lipodystrophy (Cannes). 2001;8. Abstract 0-4.
49. Roubenoff R, McDermott A, Weiss L, et al. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 1999; 13:231-9.
50. Yarasheski KE, Tebas P, Stanerson B, et al. Resistance exercise training reduces hypertriglyceridernia in HIC-infected men treated with antiviral therapy. J Appl Physiol 2001; 90:133-8.
51. Bhasin S, Storer T, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000; 283:763-70.
52. Spence DW, Galantino ML, Mossberg KA, et al. Progressive resistance exercise: effect on muscle function and anthropometry of a select AIDS population. Arch Phys Med Rehabil 1990; 71:644-8.
53. Rigsby LW, Dishman RK, Jackson AW, et al. Effects of exercise training on men seropositive for the human immunodeficiency virus-1. Med Sci Sports Exerc 1992; 24:838-40.
54. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000; 133: 348-55.
55. Agin D, Kotler DP, Papandreou D, et al. Effects of whey protein and resistance exercise on body composition and muscle strength in women with HIV infection. Ann N Y Acad Sci 2000; 904:607-9.
56. Macarthur RD, Levine SD, Birk TJ. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med Sci Sports Exerc 1993; 25:684-8.
57. Smith BA, Neidig JL, Nickel JT, Mitchell GL, Para MF, Fass RJ. Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 2001; 15:693-701.
58. Von Roenn J, Armstrong D, Kotler D, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121: 393-9.
59. Oster M, Enders S, Samuels S, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121:400-8.
60. Schambelan M, Zackin R, Mulligan K, et al. Effect of testosterone (T) on the response to megestrol acetate (MA) in patients with HIV-associated wasting: a randomized, double-blind placebo-controlled trial (ACTG 313) [abstract]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). 2001; 236. Abstract 640.
61. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10:89-97.
62. Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997; 13:305-15.
63. Abrams DI, Leiser RJ, Shade, SB, et al. Short-term effects of cannabinoids on HIV-1 viral load [abstract]. In: Program and abstracts of the 13th International AIDS Conference (Durban). 2000;LbPeB7053.
64. Mulligan K, DI Abrams, RJ Leiser, M Schambelan. Body composition changes in HIV-infected men consuming self-selected diets during a placebo-controlled inpatient study of cannabinoids [abstract]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). 2001; 647:238.
65. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with AIDS wasting: a randomized, placebo-controlled trial. Ann Intern Med 1998; 129:18-26.
66. Bhasin S, Storer T, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998; 83:3155-62.
67. Dobs AS, Dempsey MA, Ladenson PW, et al. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84(3 Pt 2):611-6.
68. Rietschel P, Corcoran C, Stanley T, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31:1240-4.
69. Grinspoon S, Corcoran C, Anderson E, et al. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis 1999; 28:634-6.
70. Grinspoon S, Corcoran C, Stanley T, et al. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 2000; 85:60-5.
71. Dobs AS, Cofrancesco J, Nolten WE, et al. The use of transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 1999; 107:126-32.
72. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, effcacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84:3649-78.
73. Bhasin S. Clinical review 34: androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992; 74:1221-5.
74. Berger J, Pall L, Hall C, Simpson D, Berry P, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 1996; 10:1657-62.
75. Gold J, High H, Li Y, et al. Safety and efficacy of nandrolone decanoate for the treatment of wasting in patients with HIV infection. AIDS 1996; 10:45-52.
76. Hengge U, Baumann M, Maleba R, Brockmeyer N, Goos M. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996; 75:129-38.
77. Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr 1999; 20:137-46.
78. Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. J Am Med Assoc 1999; 281:1282-90.
79. Mulligan K, Algren H, Schambelan M. Nandrolone decanoate in HIV+ men with wasting: a randomized, double-blind, placebo-controlled study [abstract]. In: Program and abstracts of the 4th International Conference on Nutrition and HIV Infection, 2nd European Workshop on Lipodystrophy (Cannes). 2001.
80. Sattler F, Jaque S, Schroeder E, et al. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1999; 84:1268-76.
81. Grinspoon S, Corcoran C, Stanley T, et al. Mechanisms of androgen deficiency in human immunodeficiency virus-infected women with the wasting syndrome. J Clin Endocrinol Metab 2001; 86:4120-06.
82. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998; 83:2717-25.
83. Mulligan K, Zackin R, Clark RA, et al. Nandrolone decanoate increases weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial [abstract]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). 2001; 641:236.
84. Mulligan K, Grunfeld C, Hellerstein M, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77:956-62.
85. Krentz AJ, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993; 6:245-51.
86. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996; 125:873-82.
87. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor I, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125:865-72.
88. Paton N, Newton P, Sharpstone D, et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive people. AIDS 1999; 13:1995-202.
89. Lee PDK, Pivarnik JM, Bukar JG, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996; 81: 2968-75.
90. Ellis KJ, Lee PDK, Pivarnik JM, Bukar JG, Gesundheit N. Changes in body composition of human immunodeficiency virus infected males receiving insulin-like growth factor I and growth hormone. J Clin Endocrinol Metab 1996; 81:3033-8.
91. Sampaio EP, Sarno EN, Galill R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
92. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13:1047-54.
93. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr 1996; 11:247-57.
94. Reyes-Teran G, Sierra-Madero JG, del Cerro VM, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10:1501-7.
95. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000; 16: 1345-55.
96. Jacobson J, Greenspan J, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 336:1487-93.
97. Landman D, Sarai A, Sathe SS. Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin Infect Dis 1994; 18:97-9.
98. Hellerstein MK, Wu K, McGrath M, et al. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: relation to indices of cytokine production. J Acquir Immune Defic Syndr 1996; 11:258-70.
99. Ockenga J, Rohde F, Suttmann U, Herbarth L, Ballmaier M, Schedel I. Ketotifen in HIV-infected patients: effects on body weight and release of TNF-α. Eur J Clin Pharmacol 1996; 50:167-70.
100. Clarick RH, Hanekom WA, Yogev R, Chadwick EG. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics 1997; 99:354-7.
101. Fox-Wheeler S, Heller L, Salata CM, et al. Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients. Pediatrics 1999; 104(6):e73.
102. Pinto G, Blanche S, Thiriet I, Souberbielle JC, Goulet O, Brauner R. Growth hormone treatment of children with human immunodificiency virus-associated growth failure. Eur J Pediatr 2000; 159:937-8.
103. Hirschfeld S. Use of human recombinant growth hormone and human recombinant insulin-like growth factor-I in patients with human immunodeficiency virus infection. Horm Res 1996; 46:215-21.
104. Grunfeld C, Feingold KR. Body weight as essential data in the management of patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1993; 58:317-8.